Roger Pomerantz - Seres Therapeutics Chairman of the Board and Presidentident, CEO
| MCRB Stock | USD 0.83 0.09 12.16% |
Chairman
Dr. Roger Pomerantz, M.D. is the Chairman of the Board of the Company. Dr. Pomerantz also served as our President and Chief Executive Officer from June 2014 to January 2019. Since April of 2019, Dr. Pomerantz has served as the Chief Executive Officer of ContraFect Corporation a biotechnology company. Since July 2014, Dr. Pomerantz was a Partner at Flagship Pioneering, which conceives, creates, resources and develops firstincategory life sciences companies. From January 2011 to September 2013, Dr. Pomerantz was Worldwide Head of Licensing and Acquisitions and Senior Vice President at Merck Co., Inc., a pharmaceutical company, where he oversaw licensing and acquisitions for Merck Research Laboratories, the research and development division of Merck. From February 2010 to February 2013, Dr. Pomerantz served as Global Head of Infectious Diseases and Senior Vice President at Merck, where he oversaw pharmaceutical development and discovery of antibiotics, antivirals, antifungals and antiparasitic agents. Prior to Merck, Dr. Pomerantz was Global Head of Infectious Diseases for the pharmaceutical division of Johnson Johnson, Inc., a multinational medical device, consumer goods and pharmaceutical corporation, where he was responsible for antiinfective agents worldwide. He joined Johnson Johnson in August 2005 as President of Tibotec Pharmaceuticals, Inc., now Janssen Therapeutics and a subsidiary of Johnson Johnson, a pharmaceutical company focused on the treatment of infectious diseases. Dr. Pomerantz was part of the development of ten approved infectious disease drugs for diseases including HIV, HCV and tuberculosis. He serves on the board of directors of ContraFect, Rubius Therapeutics, Inc. and Intec Therapeutics, Inc since 2019.
| Age | 60 |
| Tenure | 5 years |
| Address | 101 Cambridgepark Drive, Cambridge, MA, United States, 02140 |
| Phone | 617 945 9626 |
| Web | https://www.serestherapeutics.com |
Seres Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1908) % which means that it has lost $0.1908 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.3857) %, meaning that it created substantial loss on money invested by shareholders. Seres Therapeutics' management efficiency ratios could be used to measure how well Seres Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.66, whereas Return On Tangible Assets are forecasted to decline to (0.33). At present, Seres Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 43.4 M, whereas Total Assets are forecasted to decline to about 225.8 M.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| Brian Atwood | Veracyte | 62 | |
| Iain Dukes | Iovance Biotherapeutics | 59 | |
| William Rastetter | Fate Therapeutics | 69 | |
| Peter Wirth | Syros Pharmaceuticals | 67 | |
| John Mendlein | Fate Therapeutics | 58 | |
Management Performance
| Return On Equity | -5.39 | ||||
| Return On Asset | -0.19 |
Seres Therapeutics Leadership Team
Elected by the shareholders, the Seres Therapeutics' board of directors comprises two types of representatives: Seres Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seres. The board's role is to monitor Seres Therapeutics' management team and ensure that shareholders' interests are well served. Seres Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seres Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lorence Kim, Independent Director | ||
| Kevin Horgan, Executive Vice President Chief Medical Officer | ||
| Jeff York, VP HR | ||
| David Cook, Chief Scientific Officer and Executive VP of RandD | ||
| SPHR SHRMSCP, Executive Officer | ||
| RPh Young, Executive Officer | ||
| Thomas DesRosier, Chief Legal Officer, Executive Vice President and Secretary | ||
| David Ege, Executive Officer | ||
| Michele Trucksis, Chief Medical Officer and Executive Vice President | ||
| Noubar Afeyan, Co-Founder, Lead Director and Chairman of Compensation Committee | ||
| Caroline Holda, Assistant Counsel | ||
| Dennis Ausiello, Director | ||
| Willard Dere, Director | ||
| Eric Shaff, CFO and Executive VP | ||
| David MBA, CFO VP | ||
| Peter Hutt, Director | ||
| Marella Thorell, Executive CFO | ||
| Carlo Tanzi, Head of Investor Relations and Corporate Communications | ||
| Roger Pomerantz, Chairman of the Board and Presidentident, CEO | ||
| Kristin Ainsworth, Sr Communications | ||
| Marcus Chapman, Principal Financial and Accounting Officer, Vice President - Finance | ||
| JD Esq, Executive Officer | ||
| Richard Kender, Director | ||
| Lisa MD, Executive Officer | ||
| Meryl Zausner, Director | ||
| John Aunins, CTO and Executive VP of Bioprocess and Manufacturing | ||
| Matthew Henn, Chief Scientific Officer | ||
| Kurt Graves, Director | ||
| Eric MBA, CEO President | ||
| Gregory Behar, Director | ||
| Wael Hashad, Chief Commercial Officer, Executive Vice President | ||
| David Berry, Co-Founder, Director | ||
| Werner Cautreels, Director |
Seres Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seres Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.39 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.90) % | ||||
| Operating Margin | (617.59) % | ||||
| Current Valuation | 210.55 M | ||||
| Shares Outstanding | 151.01 M | ||||
| Shares Owned By Insiders | 5.67 % | ||||
| Shares Owned By Institutions | 59.47 % | ||||
| Number Of Shares Shorted | 17.63 M | ||||
| Price To Earning | (4.04) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Seres Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 0.987 | Quarterly Revenue Growth (0.93) | Return On Assets (0.19) | Return On Equity (5.39) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.